Granules India Q4 FY26 Earnings Call Transcript Now on BSE

Granules India has filed the transcript of its Q4 and full fiscal year 2026 earnings conference call with BSE. The document covers management discussion on quarterly and annual performance for the period ended March 31, 2026.

1 min read Granules India

Granules India Earnings Call Transcript Available

Granules India Limited (NSE: GRANULES / BSE: 540735) has released the transcript of its Q4 and financial year ended March 31, 2026 earnings conference call. The document, filed with BSE, provides a comprehensive record of the company's discussion with analysts and investors regarding its quarterly and annual performance.

The earnings call typically covers the company's operational performance, financial results, and outlook for the pharmaceutical sector. As a manufacturer of Active Pharmaceutical Ingredients (APIs), Finished Dosages, and Pharmaceutical Development and Manufacturing Services (PDMS), Granules India serves customers across multiple geographies including the United States, Europe, and other regulated markets.

About the Earnings Conference Call

Earnings conference calls are a standard practice among listed companies, allowing management teams to present their quarterly results and address questions from institutional investors, analysts, and market participants. The transcript serves as an official record of these discussions.

  • Q4 and full fiscal year ended March 31, 2026 performance review
  • Management commentary on business operations and strategy
  • Responses to analyst and investor queries
  • Forward-looking statements on company outlook

Where to Access the Transcript

The full transcript has been made available on the BSE website under the company's corporate filings section. Investors and analysts can access the document using the stock code 540735 for BSE or GRANULES for NSE trading platforms. The filing is categorized under corporate announcements related to earnings and financial results.

About Granules India

Granules India is a pharmaceutical company engaged in the manufacture of APIs, Finished Dosages, and PDMS. The company operates multiple manufacturing facilities and supplies products to branded and generic pharmaceutical companies globally. With a presence in regulated markets, the company focuses on complex generic formulations and vertically integrated manufacturing capabilities.

For the complete management commentary and detailed discussion on business performance, investors are advised to refer to the official transcript available on BSE's corporate filing portal.

This article is for informational purposes only and should not be construed as investment advice. Stock investments carry market risk. Readers are advised to conduct their own research or consult a financial advisor before making investment decisions.

Disclaimer

This article is for informational purposes only and is not investment advice. Verify all figures and announcements from official exchange filings and company disclosures before making decisions.

#GRANULES INDIA LTD.-$ #GRANULES #Corporate announcement
Plans built for every investor
TRUSTED BY INVESTORS

Track Indian stocks with ZTOX AI

NSE & BSE filings, quarterly results, insider trades, and smart volume alerts — delivered on WhatsApp or Telegram. No separate app to install.

RK
VJ
SM

"ZTOX alerts helped me catch a multi-bagger stock last quarter. The insider deals notifications are absolutely game-changing for retail investors."

Rahul K., Active Trader
MOST POPULAR
Basic Plan
For active market participants
₹89/mo
Includes:
Track 20 Companies
Insider deals alert
High volume alerts
Start Free
Advanced Plan
For serious investors & traders
₹119/mo
Includes:
Track 50 Companies
All Basic plan features
Block & Preferential Deals
Start Free

No credit card required. Connect WhatsApp or Telegram in minutes.

Secure connection. Your data is always protected.